Latest Cardiovascular Disease (CVD) News
Carbamazepine co-treatment linked to subtherapeutic anticoagulative effect of warfarin.
Target levels more likely to be achieved in departments that prescribe more statins.
Follow-up of patients from ACCORD trial shows neutral effect on primary composite outcome.
Increased risk of SCD with electrocardiogram abnormalities, even in normal-weight individuals.
The drugs do not appear to prevent progression to ESRD, new meta-analysis finds.
Overall albuminuria drop may be too small for cardiovascular, renal risk protection.
Review found atrial fibrillation linked to higher risk of stroke, cardiac events, death in women.
Reduction in total primary end point events, driven by reductions in myocardial infarction, stroke.
After adjustment for multiple variables, PP linked to all outcomes except stroke, cardiovascular death.
Serious hypoglycemia linked to progression of CAC only in standard therapy group of VA Diabetes Trial.
180 mg/dL or greater tied to worse outcomes for most patients; not for those with insulin-treated diabetes.
Independent correlation persisted after adjustment for cardiovascular risk factors.
ERN together with statin reduces apoB-48 by lowering fasting and postprandial secretion rate.
Increased left ventricular mass found in donors with even mild decreases in renal function.
Decrease in age-adjusted death rates from 2000 to 2012; increase from 2012 to 2014.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)